Received by email:

File: Press Release 2.19.2019 Imagin Q1 Investor Call NoticePR_final.docx


IMAGIN MEDICAL TO REPORT FIRST FISCAL QUARTER 2019 FINANCIAL RESULTS ON FEBRUARY 27, 2019 - CONFERENCE CALL TO FOLLOW 
_________________________________________________

Vancouver, B.C. and Boston, MA, February 19, 2019 - Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Sy
--->mbol: DPD2) ("Imagin" or the "Company"), an emerging leader in the development and commercialization of advanced medic
--->al imaging technologies, announced today that its financial results for the first fiscal quarter ended December 31, 20
--->18, will be released after market close on Wednesday, February 27, 2019. 

Imagin management will host a conference call at 5:00 p.m. ET to review the financial results and discuss business dev
--->elopments in the period.

Fiscal First Quarter 2019 Results Conference Call Details:
 
Date:  February 27, 2019
 
Time:  5:00 p.m. ET
 
Live Call: 888-428-7458 (Canada and the United States)
862-298-0702 (International)

Replay:  919-882-2331 
Replay ID: 43992

The call will also be broadcast live and archived on the Company's website at www.imaginmedical.com  under "Events & P
--->resentations."
 
About Imagin Medical

Imagin Medical is a surgical imaging company focused on establishing a new standard of care in visualizing cancer duri
--->ng minimally invasive surgeries (MIS). The Company believes its first product, the i/Blue Imaging(TM) System, will dra
--->matically improve surgeons' ability to visualize cancerous cells by producing higher-quality images more quickly compa
--->red with current methods. Based on advanced optics and light sensors, the i/Blue Imaging System employs patented ultra
--->sensitive imaging technology and offers easy-to-use viewing options for more accurate resection. The Company's initial
---> focus is bladder cancer. Learn more at www.imaginmedical.com.

Forward-Looking Statements 

Information set forth in the corporate presentation referenced in this press release contains forward-looking statemen
--->ts. These statements reflect management's current estimates, beliefs, intentions and expectations; they are not guaran
--->tees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and tha
--->t actual performance may be affected by a number of material factors, many of which are beyond the Company's control. 
--->Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, inten
--->tions and expectations expressed or implied in the forward-looking information. Specifically, there is no assurance th
--->e Company's imaging system will work in the manner expected.  Except as required under applicable securities legislati
--->on, the Company undertakes no obligation to publicly update or revise forward-looking information. The CSE has neither
---> approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accu
--->racy of this news release.

Contact:

Stephen Kilmer, Investor Relations 
Telephone: 647-872-4849
Email: stephen@kilmerlucas.com 

Jim Hutchens, President & CEO
Telephone: 833-246-2446


NR-2019-IME #29



File: Press Release 2.19.2019 Imagin Q1 Investor Call NoticePR_final.pdf

    IMAGIN MEDICAL TO REPORT FIRST FISCAL QUARTER 2019 FINANCIAL
      RESULTS ON FEBRUARY 27, 2019   CONFERENCE CALL TO FOLLOW
                     _________________________________________________

Vancouver, B.C. and Boston, MA, February 19, 2019   Imagin Medical (CSE: IME) (OTCQB:
IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) ("Imagin" or the "Company"), an emerging leader
in the development and commercialization of advanced medical imaging technologies,
announced today that its financial results for the first fiscal quarter ended December 31, 2018,
will be released after market close on Wednesday, February 27, 2019.

Imagin management will host a conference call at 5:00 p.m. ET to review the financial results
and discuss business developments in the period.

Fiscal First Quarter 2019 Results Conference Call Details:

Date:          February 27, 2019

Time:          5:00 p.m. ET

Live Call:     888-428-7458 (Canada and the United States)
               862-298-0702 (International)

Replay:        919-882-2331
Replay ID:     43992

The call will also be broadcast live and archived on the Company's website at
www.imaginmedical.com under "Events & Presentations."

About Imagin Medical

Imagin Medical is a surgical imaging company focused on establishing a new standard of care
in visualizing cancer during minimally invasive surgeries (MIS). The Company believes its first
product, the i/Blue ImagingTM System, will dramatically improve surgeons' ability to visualize
cancerous cells by producing higher-quality images more quickly compared with current
methods. Based on advanced optics and light sensors, the i/Blue Imaging System employs
patented ultrasensitive imaging technology and offers easy-to-use viewing options for more
accurate resection. The Company's initial focus is bladder cancer. Learn more at
www.imaginmedical.com.

Forward-Looking Statements

Information set forth in the corporate presentation referenced in this press release contains
forward-looking statements. These statements reflect management's current estimates, beliefs,
intentions and expectations; they are not guarantees of future performance. The Company
cautions that all forward-looking statements are inherently uncertain, and that actual
performance may be affected by a number of material factors, many of which are beyond the
Company's control. Accordingly, actual and future events, conditions and results may differ
materially from the estimates, beliefs, intentions and expectations expressed or implied in the
forward-looking information. Specifically, there is no assurance the Company's imaging system
will work in the manner expected. Except as required under applicable securities legislation, the
 Company undertakes no obligation to publicly update or revise forward-looking information. The
CSE has neither approved nor disapproved the information contained herein and does not
accept responsibility for the adequacy or accuracy of this news release.

Contact:

Stephen Kilmer, Investor Relations
Telephone: 647-872-4849
Email: stephen@kilmerlucas.com

Jim Hutchens, President & CEO
Telephone: 833-246-2446


NR-2019-IME #29